Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026)

Vertex Pharmaceuticals has reported Cash & Equivalents for 18 years, with the latest figure at $6.1 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 23.56% year-over-year to $6.1 billion in Q2 2026; TTM through Jun 2026 was $6.1 billion, a 23.56% increase from a year earlier, with the FY2025 full-year figure at $5.1 billion, up 11.27% from the prior year.
• Cash & Equivalents was $6.1 billion for Q2 2026 at Vertex Pharmaceuticals, up from $5.5 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $11.1 billion in Q3 2023, with the low at $4.6 billion in Q4 2024.
• Average Cash & Equivalents over 5 years is $7.3 billion, with a median of $6.9 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 54.58% in 2022, then sank 55.93% in 2024.
• Over 5 years, Cash & Equivalents stood at $10.5 billion in 2022, then slipped by 1.28% to $10.4 billion in 2023, then tumbled by 55.93% to $4.6 billion in 2024, then grew by 11.27% to $5.1 billion in 2025, then advanced by 20.82% to $6.1 billion in 2026.
• The last three Cash & Equivalents figures came in at $6.1 billion (Q2 2026), $5.5 billion (Q1 2026), and $5.1 billion (Q4 2025), per Business Quant data.